Výsledky vyhledávání - "Peron, Mathilde Michelle Germaine"

The Clinical and Cost-Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia: an Evidence Review Group Evaluation of a NICE Single Technology Appraisal : Inotuzumab for the treatment of adult R/R B-cell ALL: an ERG perspective

Autor: Cox, Edward Miles, Wade, Rosalind Fay, Peron, Mathilde Michelle Germaine, Dietz, Kristina Charlotte, Eastwood, Alison Jane, Palmer, Stephen John, Griffin, Susan

The National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamacin (henceforth inotuzumab), to submit clinical and cost-effectiveness evidence for inotuzumab, as part of NICE’s Single Technology A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::fb922894ab836afc56ab5471cc444886
https://eprints.whiterose.ac.uk/147007/1/Revised_Inotuzumab_Review_01.02.2019.docx

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání